0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Letters   |    
Lower Risk for Body Weight Gain and Better Control of Appetite After Switching Risperidone to Paliperidone in a Schizoaffective Patient
Yi-Cheng Hou, M.Sc.; Chien-Han Lai, M.D.
The Journal of Neuropsychiatry and Clinical Neurosciences 2014;26:E36-E37. doi:10.1176/appi.neuropsych.13040092
View Author and Article Information

The authors report no financial relationship with commercial interests.

Department of Nutrition, Buddhist Tzu-Chi General Hospital, Taipei Branch, New Taipei City, Taiwan

Department of Psychiatry, Cheng Hsin General Hospital, Taipei City, Taiwan, ROC

Send correspondence to Dr. Lai; email: stephenlai99@gmail.com

Copyright © 2014 by the American Psychiatric Association

Extract

To the Editor: Paliperidone, a metabolite of risperidone, can also treat schizoaffective disorder. Its characteristics in metabolic profile remain controversial in recent years.1,2 However, I want to present a schizoaffective patient with a lower risk for body weight gain and a better control of appetite after switching from risperidone to paliperidone.

Figures in this Article

First Page Preview

View Large
First page PDF preview
Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

+

References

Yang  LP:  Oral paliperidone: a review of its use in the management of schizoaffective disorder.  CNS Drugs 2011; 25:523–538
[CrossRef] | [PubMed]
 
Nussbaum  A;  Stroup  TS:  Paliperidone for schizophrenia.  Cochrane Database Syst Rev 2008;2:CD006369
[PubMed]
 
Nasrallah  HA:  Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.  Mol Psychiatry 2008; 13:27–35
[CrossRef] | [PubMed]
 
Schreiner  A;  Niehaus  D;  Shuriquie  NA  et al:  Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.  J Clin Psychopharmacol 2012; 32:449–457
[CrossRef] | [PubMed]
 
Meltzer  HY;  Bobo  WV;  Nuamah  IF  et al:  Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.  J Clin Psychiatry 2008; 69:817–829
[CrossRef] | [PubMed]
 
Tzimos  A;  Samokhvalov  V;  Kramer  M  et al:  Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.  Am J Geriatr Psychiatry 2008; 16:31–43
[CrossRef] | [PubMed]
 
De Hert  M;  Yu  W;  Detraux  J  et al:  Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.  CNS Drugs 2012; 26:733–759
[CrossRef] | [PubMed]
 
Hu  S;  Yao  M;  Peterson  BS  et al.  A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and beta-cell function in schizophrenic patients.  Psychopharmacology (Berl) 2013;
 
Turkoz  I;  Bossie  CA;  Lindenmayer  JP  et al:  Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.  BMC Psychiatry 2011; 11:21
[CrossRef] | [PubMed]
 
Kim  SW;  Yoon  JS;  Kim  YS  et al:  The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.  Prog Neuropsychopharmacol Biol Psychiatry 2012; 38:228–235
[CrossRef] | [PubMed]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Books
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
APA Practice Guidelines > Chapter 5.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles